Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06264921 · ClinicalTrials.gov registry record · Phase 1
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by NiKang Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT06264921 is a Phase 1 study that was terminated before completion, run by NiKang Therapeutics. The registered enrollment target is 23 participants.
The verdict
NCT06264921, a Phase 1 study, was terminated before completion, sponsored by NiKang Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).
Interventions
- DRUG NKT3447
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-02-23 |
| Est. Completion | 2025-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06264921
The ClinicalTrials.gov registry entry for NCT06264921 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NiKang Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NKT3447 is the first listed.
NCT06264921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06264921 about?
NCT06264921 is a clinical study titled "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors". The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the E...
What is the current status of trial NCT06264921?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2024-02-23. Estimated completion is 2025-04-16.
What interventions are being tested in trial NCT06264921?
The interventions under investigation include: NKT3447 (DRUG).
Who is sponsoring clinical trial NCT06264921?
This trial is sponsored by NiKang Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.